Testicular cancer is one of the most curable solid tumors, with cure rates above 95% even when it has spread. Most cases are found in men between 20 and 40. Treatment typically combines surgery to remove the affected testicle with chemotherapy or radiation, and many men are cured with surgery alone.
What's actually going on in research
Trials are testing whether some men can avoid chemotherapy after surgery, studying less toxic regimens for those who do need it, and exploring targeted therapies for the small percentage of cases that don't respond to standard treatment. Researchers are also working to reduce late effects like heart disease and hearing loss from platinum-based chemotherapy.
De-escalation trials
Studies are testing whether careful monitoring can replace chemotherapy for some early-stage cases. The goal is to spare men unnecessary treatment while catching any recurrence early enough to cure it.
Reduced-toxicity regimens
Trials are lowering chemotherapy doses or shortening treatment for certain patients. The aim is to maintain cure rates while reducing long-term side effects like heart damage and nerve problems.
Platinum-resistant disease
For the 5% of men whose cancer doesn't respond to standard chemotherapy, trials are testing high-dose chemotherapy with stem cell rescue and newer targeted drugs. Checkpoint inhibitors are being studied for certain resistant cases.
What to know before you search
Eligibility depends on cancer stage, tumor markers, type of testicular cancer, and whether this is initial treatment or a recurrence.
What types of trials are currently open
- Surveillance trials — Testing whether active monitoring with regular scans and blood tests can replace chemotherapy after surgery for early-stage cancer.
- Chemotherapy trials — Testing lower doses or shorter courses of chemotherapy to reduce side effects while maintaining cure rates.
- Relapsed disease trials — Testing high-dose chemotherapy, targeted drugs, or immunotherapy for cancer that returns after initial treatment.
- Late effects studies — Following survivors long-term to understand and prevent heart disease, hearing loss, and other delayed effects of treatment.
- Biomarker studies — Studying blood tests and genetic markers to predict which cancers need aggressive treatment and which can be watched.
Recently added Testicular Cancer trials
Complete imaging scans to help map cancer spread in testicular cancer
Testicular seminoma is a malignant tumor with a very high probability of cure. Current treatment approaches provide excellent long-term cancer outcomes. However, some standard treatments, including radiotherapy and platinum-based chemotherapy, may cause side effects both during treatment and many years after its completion. In the long term, these treatments may be associated with an increased risk of cardiovascular disease, metabolic disorders, and secondary malignancies. Because most patients with seminoma are successfully cured and have a long life expectancy, an important goal of modern cancer treatment is not only to achieve effective cancer control, but also to reduce the potential long-term adverse effects of treatment. One possible treatment approach is minimally invasive retroperitoneal lymph node dissection (RPLND), performed using laparoscopic or robot-assisted surgery. This procedure allows the disease stage to be determined more accurately by establishing whether cancer cells are present in the retroperitoneal lymph nodes. In some patients, surgery may potentially provide effective disease control without the need for subsequent radiotherapy or chemotherapy. However, currently available imaging methods, including computed tomography (CT), cannot always accurately determine whether individual retroperitoneal lymph nodes contain cancer cells. Studies have shown that in some patients undergoing RPLND for suspected lymph node involvement, no cancer cells are subsequently found in the removed lymph nodes. Therefore, there is a need to develop more accurate methods for identifying the lymph nodes that are most likely to be the first sites of cancer spread. This study investigates a method for identifying sentinel lymph nodes. Sentinel lymph nodes are the lymph nodes that first receive lymphatic drainage from the area of the primary tumor and may therefore be the first lymph nodes to which cancer cells spread. In this study, two complementary methods will be used to identify sentinel lymph nodes. The first involves the administration of a small amount of a radiopharmaceutical containing technetium-99m (Tc-99m), followed by single-photon emission computed tomography combined with computed tomography (SPECT/CT). During surgery, these lymph nodes will also be identified using a special gamma-detection device. The second method involves the use of indocyanine green (ICG), a fluorescent dye that allows the surgeon to visualize lymphatic drainage pathways and lymph nodes during surgery using near-infrared fluorescence imaging. The combination of these two methods may allow more accurate identification of sentinel lymph nodes and provide a better understanding of lymphatic drainage from testicular tumors. Participants are being invited to participate because the characteristics of their disease meet the eligibility criteria for this study. The main purpose of the study is to determine how accurately and reliably sentinel lymph nodes can be identified in patients with testicular seminoma using a combination of radionuclide and fluorescence-guided techniques. The information obtained from this study may help to develop a more individualized approach to the surgical treatment of patients with seminoma. In the future, accurate identification of sentinel lymph nodes may make it possible to reduce the extent of surgery in selected patients, potentially decreasing surgical trauma and the risk of postoperative complications. At the same time, accurate detection of cancer involvement in lymph nodes may help identify patients who require additional anticancer treatment, such as systemic chemotherapy. It is important to understand that the approach being evaluated is investigational, and its advantages over currently established approaches have not yet been conclusively demonstrated. Therefore, participation in this study cannot guarantee any additional direct medical benefit to participants. However, the information obtained from participants may contribute to improving the diagnosis and treatment of patients with testicular seminoma in the future. Participation in this study is entirely voluntary. Before making decision, participants will have the opportunity to discuss the purpose of the study, the study procedures, possible benefits and risks, and alternative treatment options with their doctor. Their decision not to participate, or to withdraw from the study at a later time, will not affect their right to receive appropriate medical care.
Receive either surgery or chemotherapy for advanced testicular cancer
The goal of this prospective observational study is to learn about the short- and long-term effects of treating men over the age of 18 with good prognosis metastatic testicular cancer with either primary retropertioneal lymph node dissection, RPLND, (for low-stage metastastic seminoma) or three doses of chemotherapy for metastastic seminoma or nonseminoma. The main question it aims to answer is: Does primary RPLND lower the risk of side-effects compared to receiving chemotherapy?
Find Testicular Cancer trials matched specifically to you
Answer 3 quick questions and we'll show you trials that fit your situation.